Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Edward Jenner
3. Louis Pasteur
4. Attenuated vaccines
5. Daniel Elmer Salmon
6. Inactivated vaccines
7. The immune system is redundant
8. Major licensed viral and bacterial vaccines
9. Persistence of immunity after vaccination
10. Fatal smallpox
11. Severe smallpox
12. Infants are difficult to immunize
13. Measles
14. The elderly are difficult to immunize
15. Influenza vaccine effectiveness
16. Herd immunity
17. Pediatric pneumococcal conjugate vaccination
18. Rotavirus vaccine
19. Burden of Rotavirus disease in the United States
20. Reconstructed image of the Rotavirus particle
21. Bovine (WC3) Rotavirus
22. Safety of pentavalent Rotavirus vaccine
23. G-serotype phase III safety and efficacy study
24. Influenza vaccines
25. Heterovariant protection by intranasal flu vaccine
26. Influenza vaccine efficacy
27. School-based intranasal influenza vaccination
28. Zoster vaccine
29. Herpes zoster incidence and CD4 memory
30. Study of zoster vaccine
31. Human Papillomavirus vaccine
32. HPV and cancer
33. The L1 protein
34. Gardasil: phase 3 prophylactic efficacy results
35. Newer strategies for vaccine development (1)
36. Newer strategies for vaccine development (2)
37. Parainfluenza recombinant vaccine
38. Bovine/human PIV3/RSV immunization
39. Vectors
40. CMV CTL response to Canarypox-pp65 vector
41. DNA plasmid vaccination
42. SHIV viral load
43. "Reverse vaccinology"
44. Non-parenteral routes of administration
45. TCI: antigen and adjuvant delivery via a patch
46. Methods of transcutaneous immunization
47. Macroflux(R) patch: comparison to 25 g needle
48. New meningococcal vaccines
49. Advantages of conjugated meningococcal vaccine
50. Malaria vaccines
51. Kaplan-Meier curves
52. TB vaccines
53. HIV vaccines
54. H5N1
55. Some strategies for H5N1 influenza vaccine
56. The 21st century vaccinology main problems

Topics Covered

• History of vaccines, with four lessons of vaccinology
• New vaccines, including those against rotavirus, influenza, zoster and human papillomaviruses
• New strategies of vaccine development, including recombinants, vectors, plasmid DNA and non|parenteral routes of administration

Links

Series:

• Viruses and Viral Diseases

Categories:

• Immunology
• Microbiology

Therapeutic Areas:

• Infectious Diseases
• Vaccines

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on October 28, 2018

Financial Disclosures

• Stanley Plotkin consults for Sanofi, Merck, GSK, Pfizer and Takeda